润达医疗: 重大投资和交易决策制度（2025年8月修订）

Core Points - The document outlines the major investment and transaction decision-making system of Shanghai RunDa Medical Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1][11] - The system aims to clarify the responsibilities and powers of the shareholders' meeting, board of directors, chairman, and management to enhance operational efficiency [1][2] Summary by Sections Investment and Transaction Definition - The term "transaction" includes activities outside daily operations such as asset purchases or sales, external investments, and relinquishing rights [1][4] Decision-Making Authority - Transactions meeting specific criteria must be submitted for board review and timely disclosure, including those where total asset value exceeds 10% of the latest audited total assets or where transaction amounts exceed 10% of net assets [2][3] Disclosure Requirements - Transactions that meet certain thresholds must be disclosed and may require shareholder meeting approval, particularly if they involve significant asset values or profits [3][4] Financial Assistance and Guarantees - Financial assistance and guarantees require board approval and may need shareholder approval if they exceed specified thresholds [8][9] Audit and Evaluation - Transactions involving significant asset values must be audited or evaluated by qualified institutions, with reports disclosed to shareholders [6][11] Related Party Transactions - Related party transactions are governed by specific regulations, ensuring compliance with the company's related party transaction decision-making system [19] Implementation and Amendments - The system is effective upon approval by the shareholders' meeting and is subject to revision by the board of directors [12][25]